Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
- Conditions
- AsthmaRhinitis, Allergic, Perennial
- Interventions
- Drug: placebo
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 73
- Registration Number
- NCT01216384
- Locations
- 🇰🇷
1268.15.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 306
- Registration Number
- NCT01215097
- Locations
- 🇨🇳
1218.65.86008 Boehringer Ingelheim Investigational Site, Dalian, China
🇨🇳1218.65.86007 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳1218.65.86011 Boehringer Ingelheim Investigational Site, Chongqing, China
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT01214616
- Locations
- 🇯🇵
1200.84.003 Boehringer Ingelheim Investigational Site, Chuo-ku, Osaka, Osaka, Japan
🇯🇵1200.84.004 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba, Japan
🇯🇵1200.84.002 Boehringer Ingelheim Investigational Site, Sakyo-ku, Kyoto, Kyoto, Japan
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 300
- Registration Number
- NCT01214239
- Locations
- 🇵🇭
1218.66.63001 Boehringer Ingelheim Investigational Site, Marikina, Philippines
🇵🇭1218.66.63002 Boehringer Ingelheim Investigational Site, San Juan, Philippines
🇨🇳1218.66.86007 Boehringer Ingelheim Investigational Site, Beijing, China
Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01214109
- Locations
- 🇨🇳
248.665.86002 Boehringer Ingelheim Investigational Site, Beijing, China
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01211197
- Locations
- 🇩🇪
1276.5.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 499
- Registration Number
- NCT01210001
- Locations
- 🇺🇸
1245.19.10070 Boehringer Ingelheim Investigational Site, Irvine, California, United States
🇺🇸1245.19.10161 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States
🇺🇦1245.19.75006 Boehringer Ingelheim Investigational Site, Lviv, Ukraine
LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01209650
- Locations
- 🇦🇺
1200.47.1 Boehringer Ingelheim Investigational Site, North Ryde, New South Wales, Australia
Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01207973
- Locations
- 🇩🇪
1272.2.1 Boehringer Ingelheim Investigational Site, Muenchen, Germany
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- Drug: BI 6727 + BIBW 2992
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 57
- Registration Number
- NCT01206816
- Locations
- 🇧🇪
1230.20.32001 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1230.20.32003 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1230.20.32002 Boehringer Ingelheim Investigational Site, Gent, Belgium